Immunovia AB (publ) (FRA:1YR)

Market Cap	10.02M +27.8%
Revenue (ttm)	63.30K -26.4%
Net Income	-13.48M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0801
Beta	n/a
RSI	46.57
Earnings Date	May 7, 2026

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1YR

Financial Performance

In 2025, Immunovia AB's revenue was 685,000, a decrease of -26.42% compared to the previous year's 931,000. Losses were -145.92 million, 90.6% more than in 2024.

Financial numbers in SEK